2Xideas AG Lowers Stock Holdings in Certara, Inc. (NASDAQ:CERT)

2Xideas AG lessened its stake in Certara, Inc. (NASDAQ:CERT - Free Report) by 62.9% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 206,014 shares of the company's stock after selling 349,499 shares during the quarter. 2Xideas AG owned approximately 0.13% of Certara worth $2,194,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Samjo Management LLC bought a new position in Certara during the fourth quarter valued at approximately $2,024,000. Wells Fargo & Company MN boosted its position in shares of Certara by 48.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock valued at $34,000 after acquiring an additional 1,047 shares during the last quarter. ExodusPoint Capital Management LP bought a new position in shares of Certara during the 4th quarter valued at approximately $11,542,000. Massachusetts Financial Services Co. MA grew its holdings in shares of Certara by 4.7% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,083,940 shares of the company's stock valued at $43,494,000 after purchasing an additional 182,042 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC increased its position in Certara by 20.5% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 12,943 shares of the company's stock worth $138,000 after purchasing an additional 2,202 shares during the last quarter. Institutional investors own 73.96% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. William Blair restated a "market perform" rating on shares of Certara in a research report on Thursday, February 27th. Stephens restated an "overweight" rating and set a $17.00 price objective on shares of Certara in a research report on Thursday, February 27th. TD Cowen began coverage on Certara in a report on Thursday, February 27th. They issued a "buy" rating and a $16.00 target price for the company. Robert W. Baird increased their price target on Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a report on Friday. Finally, Barclays lowered their price target on Certara from $13.00 to $11.00 and set an "equal weight" rating for the company in a research report on Thursday. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $15.50.

Certara Trading Up 16.6 %

Shares of NASDAQ CERT traded up $1.75 during midday trading on Friday, hitting $12.26. The company's stock had a trading volume of 6,434,331 shares, compared to its average volume of 1,121,045. Certara, Inc. has a 12-month low of $8.64 and a 12-month high of $18.68. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The firm has a market cap of $1.97 billion, a P/E ratio of -60.49, a price-to-earnings-growth ratio of 9.29 and a beta of 1.64. The business's 50 day moving average is $11.63 and its two-hundred day moving average is $11.35.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.